Association | LOD Score | Gene |
---|---|---|
1q22-24 | 3.45 | FCGR 2A/3A |
1q31 | 3.79 | |
1q41-42 | 3.3 | SLEB1 locus |
2q35-37 | 4.24 | PDCD1, SLEB2 locus |
4p16-15 | 3.84 | |
6p22-21 | 4.19 | HLA-DR, DQ, C4, TNF |
12q24 | 3.72 | |
16q12-13 | 3.85 |
Susceptibility Loci for SLE
SLE = systemic lupus erythematosus; FCGR 2A/3A = Fc gamma receptor 2A/3A; HLA = human histocompatibility antigen; C = complement; PDCD = program cell death; TNF = tumor necrosis factor
Chromosome | Population | Effect |
---|---|---|
6p21, MHC region | United States; n, 266 pts | LOD score > 3 |
6q27 | United States; n, 266 pts | LOD score > 3 |
19q13 | United States; n, 266 pts | LOD score > 3 |
12q23-24 | United States; n, 266 pts | Association |
16p13 | United States; n, 266 pts | Association |
7q21 | United States; n, 266 pts | Association |
13q33-34 | United States; n, 266 pts | Association |
Osteopontin polymorphisms | United States; n, 821 | No genetic association |
Osteopontin wild-type 1284A allele | United States; n, 821 | Trend of increased risk for secondary progressive disease |
2p, 3q, 5q, Xp | United States; 98 families; France; 90 families | Previously reported linkage not confirmed |
1p34 | United States; 98 families; France; 90 families | LOD score > .9 |
3p14 | United States; 98 families; France; 90 families | LOD score > .9 |
19q13 | United States; 98 families; France; 90 families | LOD score > .9 |
17q11, NOS2A locus, D346D | 2 African American data sets | Association |
17q22-24, PRKCA polymorphism | United Kingdom; n, 184 | Association |
6p | Canada; n, 552 affected sibling pairs | LOD, 4.4 |
2q27 | Canada; n, 552 affected sibling pairs | LOD, 2.27 |
5p15 | Canada; n, 552 affected sibling pairs | LOD, 2.09 |
18p11 | Canada; n, 552 affected sibling pairs | LOD, 1.68 |
9q21 | Canada; n, 552 affected sibling pairs | LOD, 1.58 |
1p31 | Canada; n, 552 affected sibling pairs | LOD, 1.33 |
17q | Canada; n, 552 affected sibling pairs | LOD, 1.67 |
DRB1*15 | Continental Italy; n, 609 | Association; odds ratio, 3.64 |
DRB1*07 | Continental Italy; n, 609 | Negative association; odds ratio, .60 |
6p21.3 (the HLA region), 6q14.1 and 7q34 | Portugal; n, 200 | Association |
6p21 | Germany; n, 234 and Finland; n, 195 | Association |
7p15 | France and United Kingdom; 104 families | Association in HLA-DR15-negative patients |
5p15 | Turkey; n, 197 | Association |
Susceptibility Loci for Multiple Sclerosis
HLA = human histocompatibility antigen
This activity is intended for primary care physicians, rheumatologists, and other physicians who care for patients with autoimmune diseases.
The goal of this activity is to review current evidence describing the role of genetics in autoimmune diseases.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months, that create a conflict of interest."
Medscape encourages Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape designates this educational activity for a maximum of 0.5 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
The credit that you receive is based on your user profile.
processing....
The fly sat upon the axle-tree of the chariot-wheel and said, "What a dust do I raise!"
Francis Bacon
About 3% to 5% of the US population is affected by an autoimmune disease, such as rheumatoid arthritis (RA), multiple sclerosis (MS), or systemic lupus erythematosus (SLE). Although it is still unclear what these diseases may have in common, they are generally grouped in the autoimmune category, as a dysregulation of the endogenous immune response (leading to damage of the patient's own tissues and organs) is thought to underlie their development and progression. RA and SLE predominantly affect the joints and the kidneys, whereas MS stems from demyelination in the central and peripheral nervous systems.
Far more women are affected than men, and heterogeneity in incidence is known to occur among different populations and different countries. MS, for example, manifests itself more frequently in young women of Northern rather than of Southern European descent. It is unclear whether such heterogeneity reflects genetic and/or environmental factors.
Cause and effect is still an elusive link in autoimmune diseases, and the therapies currently used reflect this lack of clear etiopathogenetic knowledge. All have a hereditary component, most probably polygenic in nature. Genetic regions and polymorphisms associated with each disease are being uncovered, and the most relevant were discussed at the 54th Annual Meeting of the American Society of Human Genetics, recently held in Toronto, Ontario, Canada.
Some gene associations have been confirmed, while others have been proven inconsistent or restricted to a specific population. More data will come in the near future, and they are expected to help in dissecting the genetic origin of autoimmune diseases and in unraveling their causes. In the meantime, we may want to remember that, sometimes, linkages and gene associations may just be flies sitting on a chariot wheel.